Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.66 |
| ▸ | CNR2 | P34972 | 7/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4701091 | 1.00 | HSD11B1 (0.66) | HSD11B1CNR2POLBMAPTKMT2A | |
| SCHEMBL6488610 | 0.95 | HSD11B1 (0.69) | HSD11B1POLBMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL4705435 | 0.90 | POLB (0.55) | HSD11B1CNR2POLBMAPTKMT2A | |
| SCHEMBL4705432 | 0.90 | POLB (0.55) | HSD11B1CNR2POLBMAPTKMT2A | |
| SCHEMBL4702704 | 0.87 | HSD11B1 (0.67) | HSD11B1POLBMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL6529014 | 0.87 | HSD11B1 (0.67) | HSD11B1POLBMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL4759219 | 0.84 | HSD11B1 (0.67) | HSD11B1CNR2POLBMAPTKMT2A | |
| SCHEMBL5243753 | 0.82 | HSD11B1 (0.72) | HSD11B1POLBMAPTKMT2ATSHR | |
| SCHEMBL4756670 | 0.82 | HSD11B1 (0.56) | HSD11B1POLBMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL4882925 | 0.82 | HSD11B1 (0.56) | HSD11B1POLBMAPTKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758882-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-01-23 | — | — | EP | claimed |
| EP-1758882-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-03-07 | — | — | EP | claimed |
| WO-2006012173-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-02-02 | — | — | WO | claimed |
| US-20050288317-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-29 | — | — | US | claimed |
| EP-1758882-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1758882-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006012173-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20050288317-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288317-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | HSD11B1 1/4885CNR2 1092/4885POLB 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.